DUBLIN, March 7, 2018 /PRNewswire/ --
The "Global Sexual Health Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Sexual Health Partnering 2012 to 2018 provides the full collection of Sexual Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Sexual Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Sexual Health deals.
The report presents financial deal terms values for Sexual Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In addition, a comprehensive appendix is provided with each report of all Sexual Health partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Report scope
Global Sexual Health Partnering 2012 to 2018 includes:
- Trends in Sexual Health dealmaking in the biopharma industry since 2012
- Analysis of Sexual Health deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Sexual Health deal contract documents
- Comprehensive access to over 3500 Sexual Health deal records
- The leading Sexual Health deals by value since 2012
- Most active Sexual Health dealmakers since 2012
Available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Sexual Health dealmaking
2.1. Introduction
2.2. Sexual Health partnering over the years
2.3. Sexual Health partnering by deal type
2.4. Sexual Health partnering by industry sector
2.5. Sexual Health partnering by stage of development
2.6. Sexual Health partnering by technology type
2.7. Sexual Health partnering by therapeutic indication
Chapter 3 - Financial deal terms for Sexual Health partnering
3.1. Introduction
3.2. Disclosed financials terms for Sexual Health partnering
3.3. Sexual Health partnering headline values
3.4. Sexual Health deal upfront payments
3.5. Sexual Health deal milestone payments
3.6. Sexual Health royalty rates
Chapter 4 - Leading Sexual Health deals and dealmakers
4.1. Introduction
4.2. Most active in Sexual Health partnering
4.3. List of most active dealmakers in Sexual Health
4.4. Top Sexual Health deals by value
Chapter 5 - Sexual Health contract document directory
5.1. Introduction
5.2. Sexual Health partnering deals where contract document available
Chapter 6 - Sexual Health dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Sexual Health therapeutic target
For more information about this report visit https://www.researchandmarkets.com/research/tc3d9v/global_sexual?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-sexual-health-partnering-2012-2018-deal-trends-players-and-financial-agreements-by-the-worlds-leading-pharma-and-biotech-companies-300609843.html
SOURCE Research and Markets
Share this article